查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1542447

全球慢性特发性便秘治疗市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势与预测

Global Chronic Idiopathic Constipation Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
出版日期: | 出版商: Value Market Research | 英文 132 Pages | 商品交期: 最快1-2个工作天内

价格

全球慢性特发性便秘治疗市场的需求预计将从2023年的120.4亿美元达到2032年的近234.2亿美元，2024-2032年研究期间的复合年增长率为7.67%。

慢性特发性便秘 (CIC) 是一种持续性胃肠道疾病，其特征是排便次数少、排便困难和排便不完全的感觉，且没有可识别的根本原因。它影响了很大一部分人口，导致不适和生活品质受损。当排除了便秘的常见原因（例如潜在的健康状况或药物副作用）后，即可诊断出 CIC。慢性特发性便秘的治疗通常包括改变生活方式、改变饮食以及旨在改善肠道功能和缓解症状的药物。治疗选择包括泻药、大便软化剂和增强胃肠蠕动的药物。 CIC 的管理根据患者的个别需求进行量身定制，并考虑症状严重程度和对先前治疗的反应等因素。

市场动态

由于人口老化、久坐的生活方式和导致胃肠道问题的饮食习惯等因素的推动，慢性特发性便秘的盛行率不断增加，慢性特发性便秘的治疗市场正在扩大。人们日益认识到 CIC 是一个重要的健康问题，这导致了人们的认识和诊断的提高，从而推动了对有效治疗方案的需求。专门针对 CIC 潜在机制的新药物的开发，例如促动力剂和增强肠道蠕动的药物，为患者提供了更好的治疗选择。药物配方和给药系统的创新，包括缓释配方和联合疗法，为更有效和更方便的治疗创造了机会。

此外，对个人化医疗的日益重视为根据患者个体情况量身定制治疗方法提供了机会。诊断技术的进步和对 CIC 病理生理学的更好理解推动了这一趋势，从而实现更有针对性和更有效的治疗。饮食调整、纤维补充剂和生物反馈疗法等非药物治疗的日益普及是另一个增长动力。这些方法为慢性特发性便秘治疗提供了补充选择，并且可以纳入综合治疗计划中。增强患者对 CIC 和可用治疗方案的认识有助于提高依从性并改善结果。远距医疗和数位医疗解决方案的扩展也有助于更好地获得 CIC 的护理和管理，特别是在服务不足的地区。然而，高昂的治疗成本和某些疗法的潜在副作用可能会阻碍慢性特发性便秘治疗市场的成长。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球慢性特发性便秘治疗市场的各个细分市场进行了包容性评估。慢性特发性便秘治疗产业的成长和趋势为本研究提供了整体方法。

市场区隔

慢性特发性便秘治疗市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略家确定相应产品或服务的目标人群以及即将到来的机会。

按药物类别

  • 5-羟色胺-4 (5-Ht4) 受体激动剂（普芦卡必利、其他）
  • 鸟苷酸环化酶-C 激动剂（普莱卡那肽、利那洛肽）
  • 泻药（匹可硫酸钠、聚卡波非等）
  • 兴奋剂（比沙可啶、Senokot 等）
  • 其他的

依给药途径

  • 口服
  • 直肠
  • 配销通路
  • 医院药房
  • 零售药局
  • 网路药局

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲慢性特发性便秘治疗市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。慢性特发性便秘治疗市场的主要参与者包括拜耳公司、艾尔建、Bausch Health、赛诺菲、武田製药公司、Sebela Pharmaceuticals、Ironwood Pharmaceuticals Inc.、Albireo Pharma Inc.、Sucampo Pharmaceuticals Inc. (Mallinckrodt) 、Janssen Pharmaceuticals Inc.。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

目录

第一章：前言

  • 报告说明
    • 客观的
    • 目标受众
    • 独特的销售主张 (USP) 和产品
  • 研究范围
  • 研究方法
    • 市场研究过程
    • 市场研究方法论

第 2 章：执行摘要

  • 市集亮点
  • 全球市场概况

第 3 章：慢性特发性便秘治疗 - 产业分析

  • 简介 - 市场动态
  • 市场驱动因素
  • 市场限制
  • 机会
  • 产业动态
  • 波特五力分析
  • 市场吸引力分析
    • 按药品类别分類的市场吸引力分析
    • 按给药途径进行的市场吸引力分析
    • 市场吸引力分析：按地区

第 4 章：价值链分析

  • 价值链分析
  • 原料分析
    • 原料清单
    • 原料厂商清单
    • 主要原物料价格走势
  • 潜在买家名单
  • 行销管道
    • 直效行销
    • 间接行销
    • 行销通路发展趋势

第 5 章：全球慢性特发性便秘治疗市场分析：依药物类别

  • 按药物类别概述
  • 按药物类别进行历史和预测数据分析
  • 5-羟色胺-4 (5-Ht4) 受体激动剂（普芦卡必利、其他）
  • 鸟苷酸环化酶-C 激动剂（普莱卡那肽、利那洛肽）
  • 泻药（匹可硫酸钠、聚卡波非等）
  • 兴奋剂（比沙可啶、Senokot 等）
  • 其他的

第 6 章：全球慢性特发性便秘治疗市场分析：依给药途径

  • 依给药途径概述
  • 按给药途径进行历史和预测资料分析
  • 口服
  • 直肠
  • 配销通路
  • 医院药房
  • 零售药局
  • 网路药局

第 7 章：全球慢性特发性便秘治疗市场分析：以地理位置

  • 区域展望
  • 介绍
  • 北美销售分析
    • 概览、历史与预测资料销售分析
    • 北美按细分市场销售分析
    • 北美按国家销售分析
    • 美国销售分析
    • 加拿大销售分析
    • 墨西哥销售分析
  • 欧洲销售分析
    • 概览、历史与预测资料销售分析
    • 欧洲按细分市场销售分析
    • 欧洲按国家销售分析
    • 英国销售分析
    • 法国销售分析
    • 德国销售分析
    • 义大利销售分析
    • 俄罗斯销售分析
    • 欧洲其他地区销售分析
  • 亚太地区销售分析
    • 概览、历史与预测资料销售分析
    • 亚太地区按细分市场销售分析
    • 亚太地区按国家销售分析
    • 中国销售分析
    • 印度销售分析
    • 日本销售分析
    • 韩国销售分析
    • 澳洲销售分析
    • 东南亚销售分析
    • 亚太地区其他地区销售分析
  • 拉丁美洲销售分析
    • 概览、历史与预测资料销售分析
    • 拉丁美洲按细分市场销售分析
    • 拉丁美洲按国家销售分析
    • 巴西销售分析
    • 阿根廷销售分析
    • 秘鲁销售分析
    • 智利销售分析
    • 拉丁美洲其他地区销售分析
  • 中东和非洲销售分析
    • 概览、历史与预测资料销售分析
    • 中东和非洲按细分市场销售分析
    • 中东和非洲按国家销售分析
    • 沙乌地阿拉伯销售分析
    • 阿联酋销售分析
    • 以色列销售分析
    • 南非销售分析
    • 中东其他地区和非洲销售分析

第 8 章：慢性特发性便秘治疗公司的竞争格局

  • 慢性特发性便秘治疗市场竞争
  • 伙伴关係/协作/协议
  • 併购
  • 新产品发布
  • 其他发展

第 9 章：公司简介

  • 顶级公司市占率分析
  • 市场集中度
  • Bayer AG
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Allergan
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Bausch Health
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Sanofi
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Takeda Pharmaceutical Company
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Sebela Pharmaceuticals
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Ironwood Pharmaceuticals Inc.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Albireo Pharma Inc.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Sucampo Pharmaceuticals Inc. (Mallinckrodt)
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Janssen Pharmaceuticals Inc. (Johnson & Johnson)
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态

註 - 在公司概况中，财务详细资讯和最新发展视情况而定，或对私人公司而言可能不包括在内

Product Code: VMR11214173

The global demand for Chronic Idiopathic Constipation Treatment Market is presumed to reach the market size of nearly USD 23.42 Billion by 2032 from USD 12.04 Billion in 2023 with a CAGR of 7.67% under the study period 2024-2032.

Chronic idiopathic constipation (CIC) is a persistent gastrointestinal condition featuring infrequent bowel movements, difficulty passing stools, and a sensation of incomplete evacuation, without an identifiable underlying cause. It affects a significant portion of the population, leading to discomfort & impaired quality of life. CIC is diagnosed when common causes of constipation, such as underlying health conditions or medication side effects, have been ruled out. Chronic idiopathic constipation treatment typically includes lifestyle modifications, dietary changes, and medications aimed at improving bowel function and alleviating symptoms. Therapeutic options include laxatives, stool softeners, and medications that enhance gastrointestinal motility. The management of CIC is tailored to individual patient needs, considering factors such as symptom severity and response to previous treatments.

MARKET DYNAMICS

The chronic idiopathic constipation treatment market is expanding due to the increasing prevalence of CIC, driven by factors such as aging populations, sedentary lifestyles, and dietary habits that contribute to gastrointestinal issues. The growing recognition of CIC as a significant health concern has led to increased awareness and diagnosis, thereby driving demand for effective treatment options. The development of new medications that specifically target the mechanisms underlying CIC, such as prokinetic agents and drugs that enhance gut motility, offers improved therapeutic options for patients. Innovations in drug formulations and delivery systems, including extended-release formulations and combination therapies, create opportunities for more effective and convenient treatments.

In addition, the rising emphasis on personalized medicine presents opportunities for tailored treatment approaches based on individual patient profiles. This trend is bolstered by progress in diagnostic technologies and a better understanding of the pathophysiology of CIC, allowing for more targeted and effective therapies. The increasing adoption of non-pharmacological treatments, such as dietary modifications, fiber supplements, and biofeedback therapy, is another growth driver. These approaches offer complementary options for chronic idiopathic constipation treatment and can be integrated into comprehensive treatment plans. Enhanced patient awareness about CIC and available treatment options contributes to higher adherence and improved outcomes. The expansion of telemedicine and digital health solutions is also facilitating better access to care and management of CIC, particularly in underserved regions. However, high treatment costs and potential side effects of some therapies may hinder chronic idiopathic constipation treatment market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Chronic Idiopathic Constipation Treatment. The growth and trends of Chronic Idiopathic Constipation Treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Chronic Idiopathic Constipation Treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

  • Serotonin-4 (5-Ht4) Receptor Agonist (Prucalopride, Others)
  • Guanylate Cyclase-C Agonist (Plecanatide, Linaclotide)
  • Laxatives (Sodium Picosulphate, Polycarbophil, Others)
  • Stimulants (Bisacodyl, Senokot, Others)
  • Others

By Route of Administration

  • Oral
  • Rectal
  • Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Chronic Idiopathic Constipation Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Chronic Idiopathic Constipation Treatment market include Bayer AG, Allergan, Bausch Health, Sanofi, Takeda Pharmaceutical Company, Sebela Pharmaceuticals, Ironwood Pharmaceuticals Inc., Albireo Pharma Inc., Sucampo Pharmaceuticals Inc. (Mallinckrodt), Janssen Pharmaceuticals Inc. (Johnson & Johnson). This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. CHRONIC IDIOPATHIC CONSTIPATION TREATMENT - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Drug Class
    • 3.7.2 Market Attractiveness Analysis By Route of Administration
    • 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET ANALYSIS BY DRUG CLASS

  • 5.1. Overview By Drug Class
  • 5.2. Historical and Forecast Data Analysis By Drug Class
  • 5.3. Serotonin-4 (5-Ht4) Receptor Agonist (Prucalopride, Others) Historic and Forecast Sales By Regions
  • 5.4. Guanylate Cyclase-C Agonist (Plecanatide, Linaclotide) Historic and Forecast Sales By Regions
  • 5.5. Laxatives (Sodium Picosulphate, Polycarbophil, Others) Historic and Forecast Sales By Regions
  • 5.6. Stimulants (Bisacodyl, Senokot, Others) Historic and Forecast Sales By Regions
  • 5.7. Others Historic and Forecast Sales By Regions

6. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

  • 6.1. Overview By Route of Administration
  • 6.2. Historical and Forecast Data Analysis By Route of Administration
  • 6.3. Oral Historic and Forecast Sales By Regions
  • 6.4. Rectal Historic and Forecast Sales By Regions
  • 6.5. Distribution Channel Historic and Forecast Sales By Regions
  • 6.6. Hospital Pharmacies Historic and Forecast Sales By Regions
  • 6.7. Retail Pharmacies Historic and Forecast Sales By Regions
  • 6.8. Online Pharmacies Historic and Forecast Sales By Regions

7. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET ANALYSIS BY GEOGRAPHY

  • 7.1. Regional Outlook
  • 7.2. Introduction
  • 7.3. North America Sales Analysis
    • 7.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.3.2 North America By Segment Sales Analysis
    • 7.3.3 North America By Country Sales Analysis
    • 7.3.4 United States Sales Analysis
    • 7.3.5 Canada Sales Analysis
    • 7.3.6 Mexico Sales Analysis
  • 7.4. Europe Sales Analysis
    • 7.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.4.2 Europe By Segment Sales Analysis
    • 7.4.3 Europe By Country Sales Analysis
    • 7.4.4 United Kingdom Sales Analysis
    • 7.4.5 France Sales Analysis
    • 7.4.6 Germany Sales Analysis
    • 7.4.7 Italy Sales Analysis
    • 7.4.8 Russia Sales Analysis
    • 7.4.9 Rest Of Europe Sales Analysis
  • 7.5. Asia Pacific Sales Analysis
    • 7.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.5.2 Asia Pacific By Segment Sales Analysis
    • 7.5.3 Asia Pacific By Country Sales Analysis
    • 7.5.4 China Sales Analysis
    • 7.5.5 India Sales Analysis
    • 7.5.6 Japan Sales Analysis
    • 7.5.7 South Korea Sales Analysis
    • 7.5.8 Australia Sales Analysis
    • 7.5.9 South East Asia Sales Analysis
    • 7.5.10 Rest Of Asia Pacific Sales Analysis
  • 7.6. Latin America Sales Analysis
    • 7.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.6.2 Latin America By Segment Sales Analysis
    • 7.6.3 Latin America By Country Sales Analysis
    • 7.6.4 Brazil Sales Analysis
    • 7.6.5 Argentina Sales Analysis
    • 7.6.6 Peru Sales Analysis
    • 7.6.7 Chile Sales Analysis
    • 7.6.8 Rest of Latin America Sales Analysis
  • 7.7. Middle East & Africa Sales Analysis
    • 7.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.7.2 Middle East & Africa By Segment Sales Analysis
    • 7.7.3 Middle East & Africa By Country Sales Analysis
    • 7.7.4 Saudi Arabia Sales Analysis
    • 7.7.5 UAE Sales Analysis
    • 7.7.6 Israel Sales Analysis
    • 7.7.7 South Africa Sales Analysis
    • 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE CHRONIC IDIOPATHIC CONSTIPATION TREATMENT COMPANIES

  • 8.1. Chronic Idiopathic Constipation Treatment Market Competition
  • 8.2. Partnership/Collaboration/Agreement
  • 8.3. Merger And Acquisitions
  • 8.4. New Product Launch
  • 8.5. Other Developments

9. COMPANY PROFILES OF CHRONIC IDIOPATHIC CONSTIPATION TREATMENT INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Market Concentration Rate
  • 9.3. Bayer AG
    • 9.3.1 Company Overview
    • 9.3.2 Company Revenue
    • 9.3.3 Products
    • 9.3.4 Recent Developments
  • 9.4. Allergan
    • 9.4.1 Company Overview
    • 9.4.2 Company Revenue
    • 9.4.3 Products
    • 9.4.4 Recent Developments
  • 9.5. Bausch Health
    • 9.5.1 Company Overview
    • 9.5.2 Company Revenue
    • 9.5.3 Products
    • 9.5.4 Recent Developments
  • 9.6. Sanofi
    • 9.6.1 Company Overview
    • 9.6.2 Company Revenue
    • 9.6.3 Products
    • 9.6.4 Recent Developments
  • 9.7. Takeda Pharmaceutical Company
    • 9.7.1 Company Overview
    • 9.7.2 Company Revenue
    • 9.7.3 Products
    • 9.7.4 Recent Developments
  • 9.8. Sebela Pharmaceuticals
    • 9.8.1 Company Overview
    • 9.8.2 Company Revenue
    • 9.8.3 Products
    • 9.8.4 Recent Developments
  • 9.9. Ironwood Pharmaceuticals Inc.
    • 9.9.1 Company Overview
    • 9.9.2 Company Revenue
    • 9.9.3 Products
    • 9.9.4 Recent Developments
  • 9.10. Albireo Pharma Inc.
    • 9.10.1 Company Overview
    • 9.10.2 Company Revenue
    • 9.10.3 Products
    • 9.10.4 Recent Developments
  • 9.11. Sucampo Pharmaceuticals Inc. (Mallinckrodt)
    • 9.11.1 Company Overview
    • 9.11.2 Company Revenue
    • 9.11.3 Products
    • 9.11.4 Recent Developments
  • 9.12. Janssen Pharmaceuticals Inc. (Johnson & Johnson)
    • 9.12.1 Company Overview
    • 9.12.2 Company Revenue
    • 9.12.3 Products
    • 9.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Drug Class (USD MN)
  • Serotonin-4 (5-Ht4) Receptor Agonist (Prucalopride, Others) Market Sales By Geography (USD MN)
  • Guanylate Cyclase-C Agonist (Plecanatide, Linaclotide) Market Sales By Geography (USD MN)
  • Laxatives (Sodium Picosulphate, Polycarbophil, Others) Market Sales By Geography (USD MN)
  • Stimulants (Bisacodyl, Senokot, Others) Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By Route of Administration (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Rectal Market Sales By Geography (USD MN)
  • Distribution Channel Market Sales By Geography (USD MN)
  • Hospital Pharmacies Market Sales By Geography (USD MN)
  • Retail Pharmacies Market Sales By Geography (USD MN)
  • Online Pharmacies Market Sales By Geography (USD MN)
  • Global Chronic Idiopathic Constipation Treatment Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Chronic Idiopathic Constipation Treatment Report
  • Market Research Process
  • Market Research Methodology
  • Global Chronic Idiopathic Constipation Treatment Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Drug Class
  • Market Attractiveness Analysis By Route of Administration
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Drug Class (USD MN)
  • Serotonin-4 (5-Ht4) Receptor Agonist (Prucalopride, Others) Market Sales By Geography (USD MN)
  • Guanylate Cyclase-C Agonist (Plecanatide, Linaclotide) Market Sales By Geography (USD MN)
  • Laxatives (Sodium Picosulphate, Polycarbophil, Others) Market Sales By Geography (USD MN)
  • Stimulants (Bisacodyl, Senokot, Others) Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By Route of Administration (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Rectal Market Sales By Geography (USD MN)
  • Distribution Channel Market Sales By Geography (USD MN)
  • Hospital Pharmacies Market Sales By Geography (USD MN)
  • Retail Pharmacies Market Sales By Geography (USD MN)
  • Online Pharmacies Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.